Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diversa awarded US grant for anthrax test:

This article was originally published in Clinica

Executive Summary

Diversa has received funds to develop an antibody-based test for anthrax infection. The $3.7m grant, from the US National Institute of Allergy and Infectious Diseases (NIAD), will also cover the development of therapeutic antibodies. The San Diego, California firm will use its proteomics technology and human antibody platform to screen for highly selective antibodies to new anthrax targets. Currently, anthrax testing is done through either time-consuming microbial culture or the newer PCR tests, which have been controversial.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel